Company Management to discuss the benefits of Hemodiafiltration therapy and
Quality of Life for End-Stage Renal Disease Patients
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient, while addressing the critical financial and clinical needs of the care provider, today announced that it exhibited at the XLV ERA-EDTA Congress in Stockholm, Sweden.
Independent studies have demonstrated reductions of up to 35% in mortality risk using hemodiafiltration (HDF) therapy in place of other standard hemodialysis therapies. Additionally, reductions in drug requirements, lower morbidity and lower infection rates have been demonstrated in a range of studies substituting hemodiafiltration for hemodialysis.
The Nephros HDF system is designed to remove a range of harmful substances more effectively and more cost-effectively than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros's OLpur MD and H2H technologies are currently in pre-approval clinical trials in the U.S.
"Nephros's HDF technology represents a new standard of therapy for ESRD
patients," said Norman J. Barta, Chairman and CEO of Nephros. "Our OLpur MD
hemodiafilter series and our H2H module technologies are designed to
provide a cost-effective and user-friendly means for hospitals and clinics
to upgrade to mid-dilution HDF therapy with
|SOURCE Nephros, Inc.|
Copyright©2008 PR Newswire.
All rights reserved